data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzdoNTEydjM0MS4zMjZIMHoiLz48cGF0aCBmaWxsPSIjRkY5ODExIiBkPSJNMCA4NS4zMzdoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjNkRBNTQ0IiBkPSJNMCAzMTIuODg4aDUxMnYxMTMuNzc1SDB6Ii8+PGNpcmNsZSBmaWxsPSIjMDA1MkI0IiBjeD0iMjU2IiBjeT0iMjU2IiByPSI0My44OTYiLz48Y2lyY2xlIGZpbGw9IiNGRkYiIGN4PSIyNTYiIGN5PSIyNTYiIHI9IjI3LjQzNCIvPjxwYXRoIGZpbGw9IiMwMDUyQjQiIGQ9Ik0yNTYgMjIyLjE0Nmw4LjQ2NCAxOS4xOTUgMjAuODU1LTIuMjY4TDI3Mi45MjcgMjU2bDEyLjM5MiAxNi45MjctMjAuODU1LTIuMjY4TDI1NiAyODkuODU0bC04LjQ2NC0xOS4xOTUtMjAuODU1IDIuMjY4TDIzOS4wNzMgMjU2bC0xMi4zOTItMTYuOTI3IDIwLjg1NSAyLjI2OHoiLz48L3N2Zz4=

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Biogen

(NASDAQ:BIIB)

Intraday

$208.50

6.04[2.98%]

After-Hours

$208.50

0[0.00%]

Perks Buy Compare Brokers

$208.50

6.04[2.98%]

At close: Apr 26

$208.50

0[0.00%]

After Hours: 7:47PM EDT

Q1 2024 Earnings were released on Wed Apr 24th, before the market open

The most recent conference call was at 8:30 AM, 4 days ago Click to view past webcast

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Biogen Stock (NASDAQ:BIIB)

Biogen Stock (NASDAQ: BIIB)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 25, 2024

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $200
Benzinga Newsdesk - 2 days ago
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Avi Kapoor - 2 days ago
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor - 2 days ago
Wedbush Maintains Neutral on Biogen, Raises Price Target to $215
Benzinga Newsdesk - 2 days ago
HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $300
Benzinga Newsdesk - 2 days ago
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Benzinga Newsdesk - 3 days ago

Wednesday, April 24, 2024

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Vandana Singh - 3 days ago
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Piero Cingari - 3 days ago
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Vandana Singh - 3 days ago
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Benzinga Newsdesk - 3 days ago
Biogen shares are trading higher following a Q1 EPS beat.
Benzinga Newsdesk - 4 days ago
Biogen Reaffirms 2024 Adjusted EPS Guidance Of $15.00-$16.00, Representing EPS Growth Of Approximately 5% Versus 2023 At The Mid-point Versus Consensus Of $15.48
Benzinga Newsdesk - 4 days ago
Biogen Q1 2024 Adj EPS $3.67 Beats $3.44 Estimate, Sales $2.291B Miss $2.311B Estimate
Benzinga Newsdesk - 4 days ago
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
Shanthi Rexaline - 4 days ago

Sunday, April 21, 2024

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Shanthi Rexaline - 6 days ago

Friday, April 19, 2024

Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $270
Benzinga Newsdesk - Apr 19, 2024, 10:53AM

Thursday, April 18, 2024

Biogen Unusual Options Activity For April 18
Benzinga Insights - Apr 18, 2024, 2:46PM

Wednesday, April 17, 2024

Wedbush Maintains Neutral on Biogen, Lowers Price Target to $213
Benzinga Newsdesk - Apr 17, 2024, 12:56PM

Friday, April 12, 2024

Biogen Unusual Options Activity
Benzinga Insights - Apr 12, 2024, 2:17PM
B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $260
Benzinga Newsdesk - Apr 12, 2024, 8:00AM

Thursday, April 11, 2024

Where Biogen Stands With Analysts
Benzinga Insights - Apr 11, 2024, 1:01PM
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $240
Benzinga Newsdesk - Apr 11, 2024, 8:49AM

Tuesday, April 09, 2024

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Apr 9, 2024, 1:35PM

Thursday, April 04, 2024

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $215
Benzinga Newsdesk - Apr 4, 2024, 9:36AM

Wednesday, April 03, 2024

Looking Into Biogen's Recent Short Interest
Benzinga Insights - Apr 3, 2024, 3:45PM

Monday, April 01, 2024

Reported Earlier, Eisai Completed Submission Of LEQEMBI® Supplemental Biologics License Application For IV Maintenance Dosing For The Treatment Of Early Alzheimer's Disease To The U.S. FDA
Benzinga Newsdesk - Apr 1, 2024, 2:17AM

Monday, March 25, 2024

Forecasting The Future: 18 Analyst Projections For Biogen
Benzinga Insights - Mar 25, 2024, 1:00PM
Truist Securities Reiterates Buy on Biogen, Maintains $340 Price Target
Benzinga Newsdesk - Mar 25, 2024, 11:57AM

Friday, March 22, 2024

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Vandana Singh - Mar 22, 2024, 1:44PM

Wednesday, March 20, 2024

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Mar 20, 2024, 1:35PM

Tuesday, March 19, 2024

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Mar 19, 2024, 1:35PM

Monday, March 18, 2024

Spotlight on Biogen: Analyzing the Surge in Options Activity
Benzinga Insights - Mar 18, 2024, 3:45PM

Monday, March 11, 2024

AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
Benzinga Newsdesk - Mar 11, 2024, 9:03AM

Friday, March 08, 2024

Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
Piero Cingari - Mar 8, 2024, 9:35AM
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
Vandana Singh - Mar 8, 2024, 8:58AM
Biogen shares are trading higher after the FDA delayed its decision for Eli Lilly's Alzheimer's drug, Donanemab.
Benzinga Newsdesk - Mar 8, 2024, 7:57AM

Wednesday, March 06, 2024

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Vandana Singh - Mar 6, 2024, 4:21PM
Biogen Announced Interim 6-month Biomarker Data From Respond Study Of Spinraza In Infants And Toddlers With Spinal Muscular Atrophy After Zolgensma Treatment, Data Shows That Plasma Neurofilament Light Chain Were Reduced In Nearly All Study Participants
Benzinga Newsdesk - Mar 6, 2024, 7:42AM

Tuesday, March 05, 2024

A Closer Look at 21 Analyst Recommendations For Biogen
Benzinga Insights - Mar 5, 2024, 10:00AM
RBC Capital Reiterates Outperform on Biogen, Maintains $364 Price Target
Benzinga Newsdesk - Mar 5, 2024, 9:50AM

Monday, March 04, 2024

Biogen To Present Data At International Conference on Alzheimer's and Parkinson's Diseases Mar. 5-9
Benzinga Newsdesk - Mar 4, 2024, 4:17PM

Thursday, February 29, 2024

Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Piero Cingari - Feb 29, 2024, 4:57PM
Biogen Unusual Options Activity
Benzinga Insights - Feb 29, 2024, 3:16PM

Friday, February 23, 2024

Biogen Says QALSODY (tofersen), The First Therapy To Treat Rare, Genetic Form Of ALS, Received Positive Opinion From CHMP
Benzinga Newsdesk - Feb 23, 2024, 7:01AM

Tuesday, February 20, 2024

Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $311 Price Target
Benzinga Newsdesk - Feb 20, 2024, 12:33PM
Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $305
Benzinga Newsdesk - Feb 20, 2024, 9:56AM

Monday, February 19, 2024

Peering Into Biogen's Recent Short Interest
Benzinga Insights - Feb 19, 2024, 3:30PM

Wednesday, February 14, 2024

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Vandana Singh - Feb 14, 2024, 3:11PM
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $364
Benzinga Newsdesk - Feb 14, 2024, 9:45AM
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor - Feb 14, 2024, 7:49AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved